Clinical trials: Lung Carcinomas, Non-Small-Cell
Non-small Cell Lung Cancer Metastatic
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT…
- Trial name
- NCT01935154
- Testing
- Vx-001
- Where
- 70 sites in Czechia, France and 6 more
- Volunteers
- 221 people
- Sponsor
- Vaxon Biotech
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Non-squamous NSCLC
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
The purpose of this study is to estimate the difference in objective response rates between each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus bevacizumab arm (Arm C) in subjects with…
- Trial name
- NCT00369070
- Testing
- Bevacizumab, AMG 706, Paclitaxel
- Volunteers
- 186 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate [ORR], proportion of patients with complete response [CR] plus partial response [PR]) until 18 weeks…
- Trial name
- NCT02272413
- Testing
- BI 695502, Avastin
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 671 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung…
- Trial name
- RELATIVITY1093 (NCT06561386)
- Testing
- Nivolumab, Relatlimab, Pembrolizumab
- Where
- 329 sites in United States, Argentina and 29 more
- Volunteers
- 1,000 people
- Sponsor
- Bristol-Myers Squibb
Non-Small-Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications.
- Trial name
- NCT00172042
- Testing
- Zoledronic acid 4 mg
- Where
- 69 sites in Belgium, China and 13 more
- Volunteers
- 437 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer…
- Trial name
- NCT00080080
- Testing
- talabostat (PT-100) tablets, Docetaxel
- Where
- 10 sites in United States
- Sponsor
- Point Therapeutics
Non Small Cell Lung Cancer
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
- Trial name
- NCT02635061
- Testing
- ACY-241, Nivolumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Celgene
Advanced Solid Tumor, Non-Small Cell Lung Cancer
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05757492
- Testing
- CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Coherus Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
- Trial name
- NCT00171834
- Testing
- Patupilone
- Where
- 4 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Carcinoma
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
This first time in human study is intended for men and women at least 18 years of age who have advanced lung cancer which has grown or returned after being treated.
- Trial name
- NCT02592577
- Testing
- Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 28 people
- Sponsor
- Adaptimmune
Brain Metastases From Non-small Cell Lung Cancer
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT01657799
- Testing
- Veliparib, Whole brain radiation therapy
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Squamous Non-small Cell Lung Cancer
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
This study is a randomized, controlled, double-blind, multi-center phase III registration clinical trial, aiming to observe, compare and evaluate the efficacy and safety of HB0025 combined with paclitaxel + carboplatin compared…
- Trial name
- NCT07360132
- Testing
- Carboplatin Injection, Paclitaxel Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Nonsmall-cell Lung Cancer
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
- Trial name
- NCT06813365
- Testing
- DZD6008
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Dizal Pharmaceuticals
Advanced Squamous Non-Small Cell Lung Carcinoma
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450…
- Trial name
- NCT05718167
- Testing
- TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection
- Where
- 4 sites in China
- Volunteers
- 570 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Small-Cell Lung Carcinoma
Phase II Iressa Versus Vinorelbine (INVITE)
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day…
- Trial name
- NCT00256711
- Testing
- Gefitinib, Vinorelbine
- Where
- 55 sites in Australia, Brazil and 8 more
- Volunteers
- 192 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a randomized Phase 3 study comparing pemetrexed and cisplatin combination to gemcitabine and cisplatin for the treatment of Non Small Cell Lung Cancer (NCSLC).
- Trial name
- NCT00087711
- Testing
- pemetrexed, gemcitabine, cisplatin
- Where
- 134 sites in United States, Argentina and 25 more
- Volunteers
- 1,713 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.